Table 4 SARS-CoV-2-related infections, hospitalizations, and deaths among study participants.

From: Immunogenicity and safety of CoronaVac vaccine in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up

Outcome

N

%

Monitoring children and adolescents

640

100.0

Suspected SARS-CoV-2 infection

209

32.7

Confirmed COVID-19 diagnosis

56

8.75

Hospitalizations

0

0.00

Deaths

0

0.00

Back to article page